Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Synosia Licenses Rufinamide From Novartis In Anxiety, Bipolar Indications

This article was originally published in The Pink Sheet Daily

Executive Summary

The sodium channel blocker could have advantages over selective serotonin reuptake inhibitors, CEO tells “The Pink Sheet” DAILY.

You may also be interested in...



Synosia Will Initiate Phase II Studies Of Rufinamide In Anxiety, Bipolar Disorders In March

Company will evaluate 500 mg and 1 gm doses of the drug, after assessing three different doses in a proof-of-concept study.

Synosia Will Initiate Phase II Studies Of Rufinamide In Anxiety, Bipolar Disorders In March

Company will evaluate 500 mg and 1 gm doses of the drug, after assessing three different doses in a proof-of-concept study.

Roche Deal Gives Synosis A Leg Up In Central Nervous System Space

The newly launched company will develop five discontinued Roche central nervous system drug candidates.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS065949

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel